In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition
暂无分享,去创建一个
[1] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[2] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[3] Leonardo L. G. Ferreira,et al. Molecular Docking and Structure-Based Drug Design Strategies , 2015, Molecules.
[4] J. Minna,et al. Inhibition of EGFR Signaling: All Mutations Are Not Created Equal , 2005, PLoS medicine.
[5] Alessandro Pedretti,et al. Assessing drug-likeness--what are we missing? , 2008, Drug discovery today.
[6] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[7] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[8] Michael Peyton,et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.
[9] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[10] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[11] Shuhang Wang,et al. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. , 2017, Cancer letters.
[12] P. Lyu,et al. Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors. , 2013, Journal of medicinal chemistry.
[13] M. Meyerson,et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.
[14] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[15] R. Bernards,et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. , 2014, Cancer discovery.
[16] P. Jänne,et al. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. , 2005, Cancer research.
[17] William Pao,et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.
[18] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[19] A. Gemma,et al. F1000 highlights , 2010 .
[20] David A. Evans,et al. 3D QSAR Methods: Phase and Catalyst Compared , 2007, J. Chem. Inf. Model..
[21] Sreenath V. Sharma,et al. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.
[22] L. Sequist,et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies , 2015, Clinical Cancer Research.
[23] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[24] Shadma Parveen,et al. Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206 , 2014, PloS one.
[25] Stuart Thomson,et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.
[26] Haikuo Zhang,et al. Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors , 2016 .
[27] Aleksandra Markovets,et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.
[28] M. Kris,et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[30] G. Giaccone,et al. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib , 2014, Cancer.
[31] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] William Pao,et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. , 2012, Cancer discovery.
[33] Matthew Meyerson,et al. Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255 , 2004, Cancer Research.
[34] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[35] Juswinder Singh,et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. , 2013, Cancer discovery.
[36] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[37] J. Engelman,et al. Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer , 2013, Science Signaling.
[38] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[39] A. Adjei,et al. The clinical development of MEK inhibitors , 2014, Nature Reviews Clinical Oncology.
[40] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[41] A. Gazdar,et al. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.
[42] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.
[43] Yan Sun,et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.
[44] M. Ladanyi,et al. Characteristics of Lung Cancers Harboring NRAS Mutations , 2013, Clinical Cancer Research.
[45] G. Getz,et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.
[46] L. Borsu,et al. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. , 2015, JAMA oncology.
[47] M. Rehan. An Anti‐Cancer Drug Candidate OSI‐027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms , 2017, Journal of cellular biochemistry.
[48] W. Gullick,et al. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. , 2006, European journal of cancer.
[49] Shadma Parveen,et al. Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches , 2014, PloS one.
[50] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[51] M. Rivera,et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. , 2007, Cancer research.
[52] J. Neal,et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.
[53] Gregory J Riely,et al. Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials , 2009, Clinical Cancer Research.
[54] T. Boggon,et al. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.
[55] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[56] Haizhen Zhong,et al. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. , 2009, Journal of molecular graphics & modelling.
[57] W. Pao,et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.
[58] William Pao,et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.